Bladder Cancer BioMarkers: Optimal Utilization for Diagnosis and Recurrence: EVERYDAY UROLOGY- Full text article

Everyday Urology-Oncology Insights: Volume 1, Issue 3

Voided urine cytology has been the gold standard for detecting bladder cancer since 1945. Its specificity nears 90%, meaning that a positive result is highly reliable. But cytology is unreliable for detection of low grade tumors such that only about 20% to 30% of low grade bladder tumors are identified using cytology.  Furthermore, up to one-third of cytology specimens are considered atypical because of confounding factors such as instrumented sampling or recent therapy with bacillus Calmette-Guérin.13

Emerging Therapies for BCG-Unresponsive Non-muscle Invasive Bladder Cancer- EVERYDAY UROLOGY: Full Text article

Everyday Urology-Oncology Insights: Volume 1, Issue 3

About 70,000 new bladder cancer cases are diagnosed annually in the United States, and about 15,000 patients die as a result.[1) Approximately 60% to 70% of cases are non-muscle invasive bladder cancer (NMBIC). Because the incidence of NMIBC substantially exceeds its mortality rate, the best indicator of its impact is its prevalence of about 700,000 cases nationwide. 

Systemic Immunotherapy Bladder Cancer.. Get Ready! EVERYDAY UROLOGY- Full text article

Everyday Urology-Oncology Insights: Volume 1, Issue 3

Daniel George, MD, is professor of medicine and surgery and director of Genitourinary Oncology at the Duke Cancer Institute. In the following article, he provides his perspective on new developments in the use of systemic immunotherapy.

Axumin™ [Fluciclovine F18]: An Accurate Imaging Approach for Patients with Biochemically Recurrent Prostate Cancer

Prostate cancer [PCa] affects 1 man in 7 in the United States, making this the most commonly diagnosed non-cutaneous cancer in males.  Although an ever-increasing number of treatment options exist, an estimated 26,100 men will still die of the disease in the US in 2016, generally after primary local and systemic treatments for prostate cancer have failed.  One factor contributing to this statistic is the frequent inability of current diagnostic methods to reliably detect the exact location(s) of disease relapse at a time when curative treatment is still possible.  

EVERYDAY UROLOGY: The Story of the COU-AA-302 Clinical Trial: Highlights From the Journey- Full text article

Charles J Ryan MD is a leader in medical oncology and was the primary investigator for the COU-AA-302 clinical trial, which led to FDA approval of abiraterone acetate plus prednisone as the first oral therapy for treatment in chemotherapy-naïve metastatic castration-resistant prostate cancer. Dr. Ryan is Professor of Clinical Medicine and Urology and Thomas Perkins Distinguished Professor in Cancer Research, and Program Leader, Genitourinary Medical Oncology at the University of California-San Francisco Helen Diller Family Comprehensive Cancer Center in San Francisco, CA. In the following article, he reflects on the highlights of the COU-AA-302 journey, including the pioneering results and methodology of the study, as well as the voice of the study results including the secondary endpoints on patient outcomes such as pain, time to opiate use, and functional status.

EVERYDAY UROLOGY: Bone Metastases and Mortality in Prostate Cancer, Can We Be Doing More?- Full text article

Prostate cancer is the most common malignancy among US men, with an estimated annual incidence of 180,890, accounting for one in five new cancer cases in men [1]. The second-most common cause of cancer death in US men, prostate cancer is expected to claim the lives of 26,120 men in this country in 2016 [1]. For men with castration-resistant prostate cancer (CRPC), median survival ranges from nine to 34 months, depending upon numerous factors, including but not limited to, the presence of metastases, the location and  volume of metastases, the presence of co-morbidities, the degree of acknowledged and interrogated symptomatology, etc.  [2]. 

The Changing Role of the Radiologist/Nuclear Medicine Physician in the Management of Advanced Prostate Cancer Patients - EVERYDAY UROLOGY- Full text article

Everyday Urology-Oncology Insights: Volume 1, Issue 1

The several new therapies recently approved for the treatment of metastatic castrate resistant prostate cancer patients have altered the roles of various healthcare providers practicing in this space.   For example, urologists have become more actively involved in the management of castrate resistant prostate cancer patients.    With regards to imaging, the advances in therapy have created an urgent need to develop better technologies to detect and monitor metastatic disease.  Radiology and nuclear medicine practices are also changing as we expand beyond diagnostic imaging to include more longitudinal therapeutic care to our patients through the administration of radium 223 to our castrate resistant patients with symptomatic bone metastases.

Considerations in the use of Androgen Deprivation Therapy for the Treatment of Men with Advanced Prostate Cancer - EVERYDAY UROLOGY- Full text article

Everyday Urology -Oncology Insights: Volume 1, Issue 1

It was October 20, 2010, when the U.S. Food and Drug Administration asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer.  The warnings alert patients and their health care professionals to the potential risk of heart disease and diabetes in men treated with these medications. 

Embarrassment of Riches: Therapies that Improve Overall Survival in mCRPC

Everyday Urology-Oncology Insights: Volume 1, Issue 1

Before 2004, there was an unmet need for survival prolonging therapies in men with castration-resistant prostate cancer (CRPC). Palliative therapeutic options were the standard of care. As a result, there was a pervasive nihilism regarding the therapeutic management of men with advanced prostate cancer, especially after they ceased responding to androgen suppressive therapy.
Page 2 of 2
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe